Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib versus cisplatin + docetaxel as second-line treatment for EGFR-mutant non-T790M advanced non-small cell lung cancer
ChiCTR1800019695Phase 4Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Dec 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of anlotinib, cisplatin and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: progression-free survival. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
anlotinibcisplatindocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800019695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019695.